Ketamine for Obsessive-Compulsive Disorder
Phase-Based Progress Estimates
Effectiveness
Safety
Obsessive-Compulsive Disorder+1 More
Ketamine - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial will test how well ketamine works to reduce OCD symptoms compared to a placebo.
Eligible Conditions
- Obsessive-Compulsive Disorder
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Up to 6 months
Up to 6 months
improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
up to 90 minutes
Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
2 Treatment Groups
Midazolam
1 of 2
Ketamine
1 of 2
Active Control
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: Ketamine · No Placebo Group · Phase 2
Ketamine
Drug
Experimental Group · 1 Intervention: Ketamine · Intervention Types: DrugMidazolam
Drug
ActiveComparator Group · 1 Intervention: Midazolam · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,148 Previous Clinical Trials
35,679,048 Total Patients Enrolled
10 Trials studying Obsessive-Compulsive Disorder
720 Patients Enrolled for Obsessive-Compulsive Disorder
University of ConnecticutOTHER
159 Previous Clinical Trials
156,136 Total Patients Enrolled
Carolyn I Rodriguez, MD, PhDPrincipal InvestigatorStanford University
3 Previous Clinical Trials
41 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
7 Patients Enrolled for Obsessive-Compulsive Disorder
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a primary diagnosis of OCD.
You have the capacity to give informed consent.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Manitoba | 33.3% |
| California | 33.3% |
| Washington | 33.3% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Stanford University | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 33.3% |
| Met criteria | 66.7% |
How responsive is this trial?
Most responsive sites:
- Stanford University: < 24 hours
Typically responds via
| 100.0% | |
Average response time
- < 1 Day
References
- Bandeira, Igor D., Daniel H. Lins-Silva, Vitor Breseghello Cavenaghi, Ingrid Dorea-Bandeira, Daniela Faria-Guimarães, Judah L. Barouh, Ana Paula Jesus-Nunes, et al.. 2022. “Ketamine in the Treatment of Obsessive-compulsive Disorder: A Systematic Review”. Harvard Review of Psychiatry. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/hrp.0000000000000330.
- Carolyn Rodriguez 2016. "Understanding How Ketamine Brings About Rapid Improvement in OCD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02624596.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments